TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

TAVR patients with cancer face higher risks of hospital readmission, serious bleeding

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Video of Michael Reardon, MD, explaining details from the Evolute Low Risk 4-year results at TCT 2023.

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

TCT 2023 San Francisco

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

Akhil Narang, MD, director of the echocardiography laboratory at Northwestern Medicine explains the latest trends in structural heart interventional imaging. #ASE #ASE23 #ASE2023 #structuralheart #echofirst

The evolving roles of TEE and ICE in structural heart interventions

Akhil Narang, MD, explained that the two technologies can be used together to deliver high-quality patient care. 

A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

The central figure from the study "Predictors and Variation in Cardiac Rehabilitation Participation After Transcatheter Aortic Valve Replacement study 2023," showing the wide variation in the percentage of patients who receive post-TAVR rehab among TAVR patients in Michigan.

Less than one-third of TAVR patients enter cardiac rehab

Only about 30% of patients who underwent TAVR in Michigan participated in cardiac rehabilitation within 90 days after discharge.

Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment

Medtronic receives CE mark approval for Evolut FX TAVR system

The self-expanding valve, already approved by the FDA, was designed with three gold markers to boost implanter efficiency, an updated catheter tip and a more flexible delivery system.

Displaying 145 - 152 of 419
Design by Adaptive Theme